I 
115TH CONGRESS 
1ST SESSION H. R. 1732 
To amend the Controlled Substances Act to add certain synthetic substances 
to schedule I, and for other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
MARCH 27, 2017 
Mr. DENT (for himself, Mr. HIMES, and Mr. BARLETTA) introduced the fol-
lowing bill; which was referred to the Committee on Energy and Com-
merce, and in addition to the Committee on the Judiciary, for a period 
to be subsequently determined by the Speaker, in each case for consider-
ation of such provisions as fall within the jurisdiction of the committee 
concerned 
A BILL 
To amend the Controlled Substances Act to add certain 
synthetic substances to schedule I, and for other purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Synthetic Drug Con-
trol Act of 2017’’. 
VerDate Sep 11 2014 
01:16 Mar 30, 2017
Jkt 069200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H1732.IH
H1732
SSpencer on DSK4SPTVN1PROD with BILLS
SEC. 2. TREATMENT OF CERTAIN DESIGNER DRUGS AS 
SCHEDULE I CONTROLLED SUBSTANCES. 
(a) IN GENERAL.—Not later than 180 days after the 
date of enactment of this Act, the Attorney General of 
the United States shall update schedule I under section 
202(c) of the Controlled Substances Act (21 U.S.C. 
812(c)) to include, unless specifically exempted or unless 
listed in another schedule, any material, compound, mix-
ture, or preparation which contains any quantity of a sub-
stance listed in paragraphs (1) through (9), or which con-
tains the salts, isomers, and salts of isomers thereof when-
ever the existence of such salts, isomers, and salts of iso-
mers is possible within the specific chemical designation. 
The substances referred to in the preceding sentence are 
the following: 
(1) 
PHENYLALKYLAMINES.—The 
substances 
listed in this paragraph consist of the following 
phenylalkylamines: 
(A) 1-(4-Ethylphenyl)-2-(methylamino)-1- 
propanone. 
(B) 1-(4-Methoxyphenyl)-2-(methylamino)- 
1-propanone. 
(C) 2-(Ethylamino)-1-(4-methoxyphenyl)-1- 
propanone. 
(D) 
1-(1,3-Benzodioxol-5-yl)-2- 
(ethylamino)-1-propanone. 
VerDate Sep 11 2014 
01:16 Mar 30, 2017
Jkt 069200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H1732.IH
H1732
SSpencer on DSK4SPTVN1PROD with BILLS
(E) 2-(Ethylamino)-1-phenyl-1-propanone. 
(F) 
1-Phenyl-2-(1-pyrrolidinyl)-1- 
propanone. 
(G) 
1-(4-Methoxyphenyl)-2-(1- 
pyrrolidinyl)-1-propanone. 
(H) 
1-(1,3-Benzodioxol-5-yl)-2-(1- 
pyrrolidinyl)-1-propanone. 
(I) 
2-Amino-1-(4-fluorophenyl)propan-1- 
one. 
(J) 
2-(Ethylamino)-1-(4-ethylphenyl)-1- 
propanone. 
(K) 
2-(Dimethylamino)-1-phenyl-1- 
propanone. 
(L) 
1-(1,3-Benzodioxol-5-yl)-2-(1- 
pyrrolidinyl)-1-butanone. 
(M) 1-(4-Methylphenyl)-2-(1-pyrrolidinyl)- 
1-hexanone. 
(N) 2-(Methylamino)-1-phenyl-1-butanone. 
(O) 2-(Methylamino)-1-(4-methylphenyl)-1- 
butanone. 
(P) 1-(4-Methylphenyl)-2-(1-pyrrolidinyl)- 
1-butanone. 
(Q) 
1-(3,4-Dimethylphenyl)-2- 
(methylamino)-1-propanone. 
VerDate Sep 11 2014 
01:16 Mar 30, 2017
Jkt 069200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H1732.IH
H1732
SSpencer on DSK4SPTVN1PROD with BILLS
(R) 
1-(1,3-Benzodioxol-5-yl)-2- 
(dimethylamino)-1-propanone. 
(S) 2-(Benzylamino)-1-(4-methylphenyl)-1- 
propanone. 
(T) 
1-(1-Naphthyl)-2-(1-pyrrolidinyl)-1- 
pentanone. 
(U) 
1-(1,3-Benzodioxol-5-yl)-2- 
(benzylamino)-1-propanone. 
(V) 
1-(1,3-Benzodioxol-5-yl)-2- 
(benzylamino)-1-butanone. 
(W) 1-(1,3-Benzodioxol-2-yl)-2-(N-hydroxy- 
N-methylamino)-1-propanone. 
(X) 
1-(1,3-Benzodioxol-5-yl)-2- 
(dimethylamino)-1-butanone. 
(Y) 2-(Ethyl(methyl)amino)-1-phenylbutan- 
1-one. 
(Z) 1-(4-Bromophenyl)-2-(methylamino)-1- 
propanone. 
(AA) 
2-[Ethyl(methyl)amino]-1-phenyl-1- 
propanone. 
(BB) 2-(Methylamino)-1-(3-methylphenyl)- 
1-propanone. 
(CC) 2-(1-Pyrrolidinyl)-1-(2-thiophenyl)-1- 
pentanone. 
VerDate Sep 11 2014 
01:16 Mar 30, 2017
Jkt 069200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H1732.IH
H1732
SSpencer on DSK4SPTVN1PROD with BILLS
(DD) 1-(4-Fluorophenyl)-2-(methylamino)- 
1-butanone. 
(EE) 
1-(4-Methoxyphenyl)-2-(1- 
pyrrolidinyl)-1-butanone. 
(FF) 1-(4-Ethylphenyl)-2-(1-pyrrolidinyl)- 
1-butanone. 
(GG) 
1-(4-Methoxy-3-methylphenyl)-2- 
(methylamino)-1-propanone. 
(HH) 2-(Ethylamino)-1-(3-methylphenyl)- 
1-propanone. 
(II) 
2-Amino-1-(1H-indol-5-yl)-1- 
propanone. 
(JJ) 
1-Phenyl-2-(1-piperidinyl)-1-buta-
none. 
(KK) 
2-(Methylamino)-1-(2,4,5- 
trimethylphenyl)-1-propanone. 
(LL) 
1-Phenyl-2-(1-pyrrolidinyl)-1- 
heptanone. 
(MM) 
1-Phenyl-2-(1-pyrrolidinyl)-1- 
hexanone. 
(NN) 
1-(4-Fluorophenyl)-2-(1- 
pyrrolidinyl)-1-pentanone. 
(OO) 
1-(1,3-Benzodioxol-5-yl)-2- 
(dimethylamino)-1-pentanone. 
VerDate Sep 11 2014 
01:16 Mar 30, 2017
Jkt 069200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H1732.IH
H1732
SSpencer on DSK4SPTVN1PROD with BILLS
(PP) 
1-(2-Fluorophenyl)-N-methyl-2- 
propanamine. 
(QQ) 1-(2-Fluorophenyl)-2-propanamine. 
(RR) 1-(3-Fluorophenyl)-2-propanamine. 
(SS) 
1-(3-Fluorophenyl)-N-methyl-2- 
propanamine. 
(TT) 1-(4-Fluorophenyl)-2-propanamine. 
(UU) 
1-(4-Fluorophenyl)-N-methyl-2- 
propanamine. 
(VV) 1-(4-Methylphenyl)-2-propanamine. 
(WW) 
N-Ethyl-N-methyl-1-phenyl-2- 
propanamine. 
(XX) 
1-(1-Benzofuran-4-yl)-2- 
propanamine. 
(YY) 
1-(1-Benzofuran-5-yl)-2- 
propanamine. 
(ZZ) 1-(2,3-Dihydro-1-benzofuran-5-yl)-2- 
propanamine. 
(AAA) 
1-(1-Benzofuran-6-yl)-2- 
propanamine. 
(BBB) 1-(2,3-Dihydro-1-benzofuran-6-yl)- 
2-propanamine. 
(CCC) 
1-(4-Methoxyphenyl)-N-methyl-2- 
propanamine. 
VerDate Sep 11 2014 
01:16 Mar 30, 2017
Jkt 069200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\H1732.IH
H1732
SSpencer on DSK4SPTVN1PROD with BILLS
(DDD) 
N,N-Dimethyl-1-phenyl-2- 
propanamine. 
(EEE) 
1-(2,3-Dihydro-1H-inden-5-yl)-2- 
propanamine. 
(FFF) 
5,6,7,8-Tetrahydronaphtho[2,3- 
d][1,3]dioxol-6-amine. 
(GGG) 
1-[4-(Methylsulfanyl)phenyl]-2- 
propanamine. 
(HHH) 1-(4-Chlorophenyl)-2-propanamine. 
(III) 
1-(2,4,6-Trimethoxyphenyl)-2- 
propanamine. 
(JJJ) 
1-(2,4,5-Trimethoxyphenyl)-2- 
propanamine. 
(KKK) 
1-(2,5-Dimethylphenyl)-2- 
propanamine. 
(LLL) 
1-(3,4-Dimethylphenyl)-2- 
propanamine. 
(MMM) 
N-(1-Phenyl-2-propanyl)-1- 
propanamine. 
(NNN) 
1-(1,3-Benzodioxol-5-yl)-N,N-di-
methyl-2-propanamine. 
(OOO) 
N-Ethyl-1-(4-methoxyphenyl)-2- 
propanamine. 
(PPP) 
1-(1-Benzofuran-5-yl)-N-methyl-2- 
propanamine. 
VerDate Sep 11 2014 
01:16 Mar 30, 2017
Jkt 069200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6201
E:\BILLS\H1732.IH
H1732
SSpencer on DSK4SPTVN1PROD with BILLS
(QQQ) 
6,7-Dihydro-5H-indeno[5,6- 
d][1,3]dioxol-6-amine. 
(RRR) 5-Iodo-2-indanamine. 
(SSS) 
N-Methyl-6,7-dihydro-5H- 
indeno[5,6-d][1,3]dioxol-6-amine. 
(TTT) N-Methyl-2-indanamine. 
(UUU) 2-{4-[(2-Fluoroethyl)sulfanyl]-2,5- 
dimethoxyphenyl}ethanamine. 
(VVV) 
2-(8-Bromo-2,3,6,7- 
tetrahydrofuro[2,3-f][1]benzofuran-4- 
yl)ethanamine. 
(WWW) 
2-(2,5-Dimethoxy-3,4- 
dimethylphenyl)ethanamine. 
(XXX) 2-(2,5-Dimethoxy-4-methylphenyl)- 
N-(2-methoxybenzyl)ethanamine. 
(YYY) 2-(4-Ethyl-2,5-dimethoxyphenyl)-N- 
(2-methoxybenzyl)ethanamine. 
(ZZZ) 
2-(2,5-Dimethoxy-3,4- 
dimethylphenyl)-N-(2-methoxy-
benzyl)ethanamine. 
(AAAA) 
2-(2,5-Dimethoxyphenyl)-N-(2- 
methoxybenzyl)ethanamine. 
(BBBB) 2-(2,5-Dimethoxy-4-nitrophenyl)- 
N-(2-methoxybenzyl)ethanamine. 
VerDate Sep 11 2014 
01:16 Mar 30, 2017
Jkt 069200
PO 00000
Frm 00008
Fmt 6652
Sfmt 6201
E:\BILLS\H1732.IH
H1732
SSpencer on DSK4SPTVN1PROD with BILLS
(CCCC) 
1-(8-Bromofuro[2,3- 
f][1]benzofuran-4-yl)-2-propanamine. 
(DDDD) 
1-(4-Chloro-2,5- 
dimethoxyphenyl)-2-propanamine. 
(EEEE) 
1-(8-Bromo-2,3,6,7- 
tetrahydrobenzo[1,2-b:4,5-b′]difuran-4- 
yl)propan-2-amine. 
(FFFF) 
1-[4-(Ethylsulfanyl)-2,5- 
dimethoxyphenyl]-2-propanamine. 
(GGGG) 
1-(4-Ethoxy-2,5- 
dimethoxyphenyl)-2-propanamine. 
(HHHH) 
1-[2,5-Dimethoxy-4- 
(propylsulfanyl)phenyl]-2-propanamine. 
(IIII) 
6-Chloro-1,2,3,4-tetrahydro-1- 
naphthalenamine. 
(JJJJ) 
N-Methyl-3- 
phenylbicyclo[2.2.1]heptan-2-amine. 
(KKKK) 1-(2-Methoxyphenyl)-N-methyl-2- 
propanamine. 
(LLLL) 
2-[4-(Allyloxy)-3,5- 
dimethoxyphenyl]ethanamine. 
(MMMM) 4-Methyl-2-hexanamine. 
(NNNN) 
4-Methyl-5-phenyl-4,5-dihydro- 
1,3-oxazol-2-amine. 
VerDate Sep 11 2014 
01:16 Mar 30, 2017
Jkt 069200
PO 00000
Frm 00009
Fmt 6652
Sfmt 6201
E:\BILLS\H1732.IH
H1732
SSpencer on DSK4SPTVN1PROD with BILLS
(OOOO) 
N-Methyl-1-(2-thienyl)-2- 
propanamine. 
(PPPP) 
3-(Dimethylamino)-2,2- 
dimethylpropyl 4-aminobenzoate. 
(QQQQ) 4-Methyl-5-(4-methylphenyl)-4,5- 
dihydro-1,3-oxazol-2-amine. 
(RRRR) 1-Phenyl-2-(1-pyrrolidinyl)-1-pro-
panol. 
(2) 
CANNABIMIMETIC
AGENTS.—The 
sub-
stances listed in this paragraph consist of the fol-
lowing cannabimimetic agents: 
(A) 
(4-Ethyl-1-naphthyl)(1-pentyl-1H- 
indol-3-yl)methanone. 
(B) 
2-(2-Methylphenyl)-1-(1-pentyl-1H- 
indol-3-yl)ethanone. 
(C) 
(2-Methyl-1-[(1-methylpiperidin-2- 
yl)methyl]-6-nitro-1H-indol-3-yl)(2- 
naphthyl)methanone. 
(D) 
(1-Butyl-1H-indol-3-yl)(4- 
methoxyphenyl)methanone. 
(E) 
(1-Butyl-1H-indol-3-yl)(4-methyl-1- 
naphthyl)methanone. 
(F) 
[1-(5-Fluoropentyl)-1H-indol-3-yl](4- 
methyl-1-naphthyl)methanone. 
VerDate Sep 11 2014 
01:16 Mar 30, 2017
Jkt 069200
PO 00000
Frm 00010
Fmt 6652
Sfmt 6201
E:\BILLS\H1732.IH
H1732
SSpencer on DSK4SPTVN1PROD with BILLS
(G) 
{1-[(1-Methyl-2-piperidinyl)methyl]- 
1H-indol-3-yl}(1-naphthyl)methanone. 
(H) 
2-(3-Methoxyphenyl)-1-(1-pentyl-1H- 
indol-3-yl)ethanone. 
(I) 
(2-Iodophenyl){1-[(1-methyl-2- 
piperidinyl)methyl]-1H-indol-3-yl}methanone. 
(J) 
Adamantan-1-yl{1-[(1-methyl-2- 
piperidinyl)methyl]-1H-indol-3-yl}methanone. 
(K) 
1-Naphthyl(1-propyl-1H-indol-3- 
yl)methanone. 
(L) 
5-[3-(1-Naphthoyl)-1H-indol-1- 
yl]pentanenitrile. 
(M) 
3-(1-Naphthylmethyl)-1-pentyl-1H- 
indole. 
(N) 
(2-Methyl-1-propyl-1H-indol-3-yl)(1- 
naphthyl)methanone. 
(O) 1-Naphthyl[1-(4-penten-1-yl)-1H-indol- 
3-yl]methanone. 
(P) 
(4-Bromo-1-naphthyl)(1-pentyl-1H- 
indol-3-yl)methanone. 
(Q) 
(4-Fluoro-1-naphthyl)(1-pentyl-1H- 
indol-3-yl)methanone. 
(R) 
(1-Naphthyl)(1-phenyl-1H-indol-3- 
yl)methanone. 
VerDate Sep 11 2014 
01:16 Mar 30, 2017
Jkt 069200
PO 00000
Frm 00011
Fmt 6652
Sfmt 6201
E:\BILLS\H1732.IH
H1732
SSpencer on DSK4SPTVN1PROD with BILLS
(S) 
[1-(5-Chloropentyl)-1H-indol-3-yl](2- 
iodophenyl)methanone. 
(T) 
Adamantan-1-yl(1-pentyl-1H-indol-3- 
yl)methanone. 
(U) (2-Iodo-5-nitrophenyl){1-[(1-methyl-2- 
piperidinyl)methyl]-1H-indol-3-yl}methanone. 
(V) 
{1-[2-(4-Morpholinyl)ethyl]-1H-indol- 
3-yl}(2,2,3,3-tetramethylcyclopropyl)methanone. 
(W) [1-(Tetrahydro-2H-pyran-4-ylmethyl)- 
1H-indol-3-yl](2,2,3,3- 
tetramethylcyclopropyl)methanone. 
(X) 
N-(Adamantan-1-yl)-1-pentyl-1H- 
indole-3-carboxamide. 
(Y) 
N-(Adamantan-1-yl)-1-(5- 
fluoropentyl)-1H-indole-3-carboxamide. 
(Z) 
[1-(5-Chloropentyl)-1H-indol-3- 
yl](2,2,3,3-tetramethylcyclopropyl)methanone. 
(AA) [1-(3-Methylbutyl)-1H-indol-3-yl](1- 
naphthyl)methanone. 
(BB) 
N-(Adamantan-1-yl)-1-(5- 
fluoropentyl)-1H-indazole-3-carboxamide. 
(CC) 
(1-Pentyl-1H-indol-3-yl)(4-propyl-1- 
naphthyl)methanone. 
(DD) 
[1-(5-Chloropentyl)-1H-indol-3- 
yl](2,2,3,3-tetramethylcyclopropyl)methanone. 
VerDate Sep 11 2014 
01:16 Mar 30, 2017
Jkt 069200
PO 00000
Frm 00012
Fmt 6652
Sfmt 6201
E:\BILLS\H1732.IH
H1732
SSpencer on DSK4SPTVN1PROD with BILLS
(HHHH) {4-[2,6-Dimethoxy-4-(2-methyl- 
2-octanyl)phenyl]-6,6- 
dimethylbicyclo[3.1.1]hept-2-en-2-yl}methanol. 
(IIII) 
1-Naphthyl[4-(pentyloxy)-1- 
naphthyl]methanone. 
(JJJJ) 
3-{[2-(Hydroxymethyl)-2,3- 
dihydro-1H-inden-4-yl]oxy}phenyl 
4,4,4- 
trifluoro-1-butanesulfonate. 
(KKKK) 
N-(1,3-Benzodioxol-5-ylmethyl)- 
7-methoxy-2-oxo-8-(pentyloxy)-1,2-dihydro-3- 
quinolinecarboxamide. 
(LLLL) 
N-[3-(2-Methoxyethyl)-4,5-di-
methyl-2,3-dihydro-1,3-thiazol-2-ylidene]- 
2,2,3,3-tetramethylcyclopropane-1-carboxamide. 
(MMMM) 
[5-(2-Fluorophenyl)-1-pentyl- 
1H-pyrrol-3-yl](1-naphthyl)methanone. 
(NNNN) 
5-(4-Biphenylylmethyl)-N,N-di-
methyl-1H-tetrazole-1-carboxamide. 
(OOOO) 
6-Methyl-2-[(4- 
methylphenyl)amino]-4H-3,1-benzoxazin-4-one. 
(PPPP) 
4-Hydroxy-N-[2-(4- 
hydroxyphenyl)ethyl]-3- 
(pentylamino)benzamide. 
VerDate Sep 11 2014 
02:35 Mar 30, 2017
Jkt 069200
PO 00000
Frm 00018
Fmt 6652
Sfmt 6201
E:\BILLS\H1732.IH
H1732
SSpencer on DSK4SPTVN1PROD with BILLS
(3) ARYLCYCLOHEXAMINES.—The substances 
listed in this paragraph consist of the following 
arylcyclohexamines: 
(A) 
1-(3-Methoxyphenyl)-N- 
propylcyclohexanamine. 
(B) 
2-(Ethylamino)-2-(3- 
methoxyphenyl)cyclohexanone. 
(C) 1-Phenylcyclohexanamine. 
(D) 
1-[1-(1-Benzothiophen-2- 
yl)cyclohexyl]piperidine. 
(E) 
1-[1-(4- 
Methylphenyl)cyclohexyl]piperidine. 
(F) 
1(4-Methoxyphenyl)-N- 
propylcyclohexanamine. 
(G) 
1-[1-(4- 
Methoxyphenyl)cyclohexyl]piperidine. 
(H) 
1-[1-(3- 
Methoxyphenyl)cyclohexyl]piperidine. 
(I) 1-Phenyl-N-propylcyclohexanamine. 
(J) 
N-(2-Methoxyethyl)-1- 
phenylcyclohexanamine. 
(K) 
N-(2-Ethoxyethyl)-1- 
phenylcyclohexanamine. 
(L) 
N-(3-Methoxypropyl)-1- 
phenylcyclohexanamine. 
VerDate Sep 11 2014 
01:16 Mar 30, 2017
Jkt 069200
PO 00000
Frm 00019
Fmt 6652
Sfmt 6201
E:\BILLS\H1732.IH
H1732
SSpencer on DSK4SPTVN1PROD with BILLS
(M) 3-[1-(1-Piperidinyl)cyclohexyl]phenol. 
(N) 
2-(4-Methoxyphenyl)-2- 
(methylamino)cyclohexanone. 
(O) 
2-(2-Chlorophenyl)-2- 
(ethylamino)cyclohexanone. 
(4) TRYPTAMINES.—The substances listed in 
this paragraph consist of the following tryptamines: 
(A) 2-(1H-Indol-3-yl)-N-methylethanamine. 
(B) N-[2-(1H-Indol-3-yl)ethyl]-N-methyl-2- 
propanamine. 
(C) N-[2-(1H-Indol-3-yl)ethyl]-N-isopropyl- 
2-propanamine. 
(D) N-[2-(1H-Indol-3-yl)ethyl]-N-propyl-1- 
propanamine. 
(E) 3-(2-(Diethylamino)ethyl)-1H-indol-4- 
yl acetate. 
(F) 
3-{2-[Isopropyl(methyl)amino]ethyl}- 
1H-indol-4-ol. 
(G) 
3-[2-(Diisopropylamino)ethyl]-1H- 
indol-4-yl acetate. 
(H) 3-{2-[Isopropyl(methyl)amino]ethyl}- 
1H-indol-4-yl acetate. 
(I) 3-[2-(Dimethylamino)ethyl]-1H-indol-4- 
yl acetate. 
VerDate Sep 11 2014 
01:16 Mar 30, 2017
Jkt 069200
PO 00000
Frm 00020
Fmt 6652
Sfmt 6201
E:\BILLS\H1732.IH
H1732
SSpencer on DSK4SPTVN1PROD with BILLS
(J) 
3-[2-(Diethylamino)ethyl]-1H-indol-4- 
ol. 
(K) 
3-[2-(Diisopropylamino)ethyl]-1H- 
indol-4-ol. 
(L) 
3-{2-[Ethyl(methyl)amino]ethyl}-1H- 
indol-4-ol. 
(M) 3-{2-[Ethyl(methyl)amino]ethyl}-1H- 
indol-4-yl acetate. 
(N) 
3-[2-(Dipropylamino)ethyl]-1H-indol- 
4-ol. 
(O) 3-[2-(Dipropylamino)ethyl]-1H-indol-4- 
yl acetate. 
(P) N-(2-(5-Methoxy-1H-indol-3-yl)ethyl)- 
N-methylpropan-2-amine. 
(Q) 
1-(5-Methoxy-1H-indol-3-yl)-2- 
propanamine. 
(R) 3-[2-(Dimethylamino)ethyl]-1H-indol- 
5-yl acetate. 
(S) N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]- 
N-propylpropan-2-amine. 
(T) N,N-Diethyl-2-(5-methoxy-1H-indol-3- 
yl)ethanamine. 
(U) N-Ethyl-2-(5-methoxy-1H-indol-3-yl)- 
N-methylethanamine. 
VerDate Sep 11 2014 
01:16 Mar 30, 2017
Jkt 069200
PO 00000
Frm 00021
Fmt 6652
Sfmt 6201
E:\BILLS\H1732.IH
H1732
SSpencer on DSK4SPTVN1PROD with BILLS
(5) BENZYLPIPERIDINES.—The substances list-
ed in this paragraph consist of the following 
benzylpiperidines: 
(A) 2-(Diphenylmethyl)piperidine. 
(B) 2-(Diphenylmethyl)pyrrolidine. 
(C) Diphenyl(2-pyrrolidinyl)methanol. 
(D) 
Methyl 
(3,4-dichlorophenyl)(2- 
piperidinyl)acetate. 
(E) 
Methyl 
(3-chlorophenyl)(2- 
piperidinyl)acetate. 
(F) 
Methyl 
(4-methylphenyl)(2- 
piperidinyl)acetate. 
(G) 
Methyl 
(4-fluorophenyl)(2- 
piperidinyl)acetate. 
(H) Ethyl phenyl(2-piperidinyl)acetate. 
(6) BENZODIAZEPINES.—The substances listed 
in 
this 
paragraph 
consist 
of 
the 
following 
benzodiazepines: 
(A) 
4-(2-Chlorophenyl)-2-ethyl-9-methyl- 
6H-thieno[3,2-f][1,2,4]triazolo[4,3- 
a][1,4]diazepine. 
(B) 
7-Bromo-5-(2-chlorophenyl)-1,3- 
dihydro-2H-1,4-benzodiazepin-2-one. 
(C) 
8-Bromo-1-methyl-6-phenyl-4H- 
[1,2,4]triazolo[4,3-a][1,4]benzodiazepine. 
VerDate Sep 11 2014 
01:16 Mar 30, 2017
Jkt 069200
PO 00000
Frm 00022
Fmt 6652
Sfmt 6201
E:\BILLS\H1732.IH
H1732
SSpencer on DSK4SPTVN1PROD with BILLS
(D) 
3-Methyl-6-[3- 
(trifluoromethyl)phenyl][1,2,4]triazolo[4,3- 
b]pyridazine. 
(7) OPIOIDS AND OPIOID-LIKE SUBSTANCES.— 
The substances listed in this paragraph consist of 
the following opioids and opioid-like substances: 
(A) 
3-[2-(2-Amino-2-propanyl)-1- 
hydroxycyclohexyl]phenol. 
(B) 
2-Methyl-N-phenyl-N-[1-(1-phenyl-2- 
propanyl)-4-piperidinyl]propanamide. 
(C) 
1-Cyclohexyl-4-(1,2- 
diphenylethyl)piperazine. 
(D) 
N-Phenyl-N-[1-(2-thiophenylethyl)-4- 
piperidinyl]acetamide. 
(8) PIPERAZINES.—The substances listed in 
this paragraph consist of the following piperazines: 
(A) 1,4-Dibenzylpiperazine. 
(B) 
1-(4-Bromo-2,5- 
dimethoxybenzyl)piperazine. 
(C) 1-(4-Fluorophenyl)piperazine. 
(D) 1-(2-Methoxyphenyl)piperazine. 
(E) 1-(4-Chlorophenyl)piperazine. 
(F) 1-(4-Methoxyphenyl)piperazine. 
(G) 1-(3-Methylbenzyl)piperazine. 
(H) 1-Benzyl-4-methylpiperazine. 
VerDate Sep 11 2014 
01:16 Mar 30, 2017
Jkt 069200
PO 00000
Frm 00023
Fmt 6652
Sfmt 6201
E:\BILLS\H1732.IH
H1732
SSpencer on DSK4SPTVN1PROD with BILLS
(9) TROPANE
AND
ALKALOIDS.—The sub-
stances listed in this paragraph consist of the fol-
lowing tropane alkaloids: 
(A) 8-Methyl-8-azabicyclo[3.2.1]oct-3-yl 4- 
fluorobenzoate. 
(B) Methyl 3-(4-fluorophenyl)-8-methyl-8- 
azabicyclo[3.2.1]octane-2-carboxylate. 
(b) INAPPLICABILITY OF OTHER PROCESS AND CON-
SIDERATIONS.—The Attorney General of the United 
States may carry out subsection (a) without regard to the 
process and considerations that are otherwise applicable 
under section 201 of the Controlled Substances Act (21 
U.S.C. 811) for adding, removing, or transferring con-
trolled substances to, from, or among the schedules under 
section 202(c) of such Act (21 U.S.C. 812(c)). 
(c) EXEMPTION FOR RESEARCH.— 
(1) EXEMPTION.—Notwithstanding subsection 
(a), a material, compound, mixture, or preparation 
described in such subsection shall not be treated as 
a controlled substance for purposes of the Controlled 
Substances Act (21 U.S.C. 801 et seq.) so long as 
the material, compound, mixture, or preparation is 
manufactured, distributed, and used exclusively for 
qualified research. 
VerDate Sep 11 2014 
01:16 Mar 30, 2017
Jkt 069200
PO 00000
Frm 00024
Fmt 6652
Sfmt 6201
E:\BILLS\H1732.IH
H1732
SSpencer on DSK4SPTVN1PROD with BILLS
(2) QUALIFIED RESEARCH DEFINED.—In this 
subsection, the term ‘‘qualified research’’ means re-
search (as such term is used in section 303(f) of the 
Controlled Substances Act (21 U.S.C. 823(f))) that 
is conducted by a practitioner who is registered 
under such section 303(f) to conduct research with 
controlled substances in schedule II, III, IV, or V 
(as described in such section 303(f)). 
(d) RULE OF CONSTRUCTION.—Nothing in this sec-
tion shall be construed to limit or affect the authority of 
the Attorney General of the United States to add, remove, 
or transfer controlled substances to, from, or among the 
schedules under section 202(c) of the Controlled Sub-
stances Act (21 U.S.C. 812(c)), including controlled sub-
stances that have been added to a schedule pursuant to 
subsection (a). 
Æ 
VerDate Sep 11 2014 
01:16 Mar 30, 2017
Jkt 069200
PO 00000
Frm 00025
Fmt 6652
Sfmt 6301
E:\BILLS\H1732.IH
H1732
SSpencer on DSK4SPTVN1PROD with BILLS